<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287677</url>
  </required_header>
  <id_info>
    <org_study_id>VIHCREC01</org_study_id>
    <nct_id>NCT00287677</nct_id>
  </id_info>
  <brief_title>Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients</brief_title>
  <official_title>Double Strategy to Induce and Expand the T Cell Repertoire by the Administration of Growth Hormone and Vaccination in HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concomitant administration of recombinant human growth hormone (rhGH) may boost the expansion
      of immune reconstitution and broaden specific T cell responses not achievable by vaccination
      alone. The main objective of that study is to test the validity of this hypothesis with
      vaccines which are routinely administered to HIV-1 patients(tetanus toxoid and hepatitis A
      virus vaccines) in order to, if proven of value, use this strategy of HIV vaccination in the
      near future. This is a pilot, randomized, clinical open label study aimed to investigate
      thymic functionality and the HIV-specific responses after administration of rhGH in HIV-1
      infected patients in highly active antiretroviral therapy (HAART) regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of a therapeutic vaccine is to control, induce and expand humoral and cellular
      immune responses capable to control HIV infection. The administration of a conventional
      vaccine results in the expansion of peripheral clones. Concomitant administration of rhGH may
      boost this expansion and reconstitute specific T cell responses not achievable by vaccination
      alone. In this study we want to investigate whether the administration of rhGH expand T cell
      repertoire and whether there is an increase in the specific cellular responses to HIV-1 and
      recall antigens and, lately, whether this responses can be further amplified after
      immunization with tetanus toxoid and hepatitis A vaccines. This Hypothesis will be evaluated
      by the measurement of thymic volume, the expansion of naïve, memory and effector cell
      subsets, analysis of thymic emigrants (TRECs) before, during and after rhGH administration
      and vaccination. Moreover, T cell receptor rearrangement, specific antibodies and cellular
      responses to antigenic peptides will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients HIV+ that recover the immunospecific responses against tetanus toxoid and Hepatitis A at 24 weeks of rhGH administration (time of treatment interruption).</measure>
    <time_frame>from 24 weeks post rhGH administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rhGH activates the thymic function.</measure>
    <time_frame>from one year post rhGH administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>This effect is lasting once the rhGH administration is interrupted.</measure>
    <time_frame>from at least one year since the last rhGH administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>growth hormone + vaccination + HAART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>growth hormone + HAART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccination + HAART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control healthy HIV negative + vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant human Growth Hormone</intervention_name>
    <description>Growth Hormone during 6 months (30UG/KG/DAY)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination</intervention_name>
    <description>Vaccination (Hepatitis A+B + tetanus toxoid) at week 16</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>HAART all over the trial</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 asymptomatic patients in HAART regimen (&gt; 6 months)

          2. Viral load &lt; 50 copies/ml

          3. Number CD4 cells &gt; 250 cells/mm3

          4. Non responders to vaccination (tetanus toxoid and/or Hepatitis A virus)

          5. Well-disposition to rhGh daily administration (6 months of treatment)

        Exclusion Criteria:

          1. AIDS outbreak

          2. Allergy or hyperreactivity to rhGH or vaccines

          3. Diabetes Mellitus

          4. Renal, hepatic, pancreatic disorders

          5. Chronic diseases

          6. Dementia

          7. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IrsiCaixa Foundation-Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lidia Ruiz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irsicaixa Foundation-Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Mª Gatell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margarita Bofill, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Irsicaixa Foundation- Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>November 3, 2009</last_update_submitted>
  <last_update_submitted_qc>November 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Germans Trias i Pujol Hospital</name_title>
    <organization>Germans Trias i Pujol Hospital</organization>
  </responsible_party>
  <keyword>Growth Hormone</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Thymopoiesis</keyword>
  <keyword>HIV-specific responses</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

